Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

- Kalincik, Tomas, Sharmin, Sifat, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trnený, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, Roos, Izanne, McCombe, Pamela, Skibina, O, Lechner-Scott, Jeanette, Willekens, B, Cartechini, E, Ozakbas, S, Alroughani, R, Kuhle, J, Patti, F, Duquette, P, Freedman, Mark S., Lugaresi, A, Khoury, SJ, Slee, M, Turkoglu, R, Hodgkinson, S, John, N, Maimone, D, Sa, MJ, van Pesch, V, Gerlach, O, Atkins, Harold, Laureys, G, Van Hijfte, L, Karabudak, R, Spitaleri, D, Csepany, T, Gouider, R, Castillo-Triviño, T, Taylor, B, Sharrack, B, Snowden, JA, Burman, Joachim, MSBase Study Group Collaborators,, MSBase Study Group Authors,, Mrabet, S, Garber, J, Sanchez-Menoyo, JL, Aguera-Morales, E, Blanco, Y, Al-Asmi, A, Weinstock-Guttman, B, Fragoso, Y, Massey, Jennifer, de Gans, K, Kermode, A, MSBase Study Group,, Sutton, Ian, Withers, Barbara, Macdonell, Richard

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

- Enjeti, Anoop K., Agarwal, Rishu, Singhal, Deepak, Tate, Courtney, Tiong, Ing Soo, Ross, David M., Blombery, Piers, Chee, Lynette, Chua, Chong Chyn, Grigg, Andrew, Hamad, Nada, Iland, Harry, Lane, Steven, Perkins, Andrew

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

- Iland, Harry J., Collins, Marnie, Hugman, Amanda, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bradstock, Ken, Bashford, John, Seymour, John F., Supple, Shane G., Catalano, Alberto, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Campbell, Lynda J.

A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

- Hertzberg, Mark, Matthews, Jane Palfrey, Abdi, Ehtesham, Green, Michael, Bonaventura, Anthony, Marlton, Paula, Cannell, Paul, Wolf, Max, Stone, Janey Malka, Dubosq, Ming-Celine, Grigg, Andrew, Ellis, David, Benson, Warwick, Browett, Peter, Horvath, Noemi, Januszewicz, Henry

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

- Iland, Harry J., Bradstock, Ken, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bashford, John, Supple, Shane G., Seymour, John F., Catalano, Alberto, Collins, Marnie, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Hugman, Amanda

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

- Hughes, Timothy P., Branford, Susan, Cooney, Julian, Leahy, Michael F., Rowlings, Philip, Catalano, John, Hertzberg, Mark, Filshie, Robin, Mills, Anthony K., Fay, Keith, Durrant, Simon, Januszewicz, Henry, White, Deborah L., Joske, David, Underhill, Craig, Dunkley, Scott, Lynch, Kevin, Grigg, Andrew, Reynolds, John, Koelmeyer, Rachel, Seymour, John F., Taylor, Kerry, Arthur, Chris, Schwarer, Anthony K., Morton, James